23 November 23-26, 2011 Starting at 08:00am
San Francisco Moscone Center, 603 Red River St
tickets from $120 Register Today >

Retina

Retina I

Sunday, June 19, 1045-1215canmeds_diagram_e
Room 206, Shaw Centre

LEARNING OBJECTIVES

At the end of this session, participants will be able to:

  • Integrate emerging treatments for wet AMD in their practice and training
  • Apply the preferred practice patterns for the treatment macular edema
  • Recognize the pros and cons of 27-gauge vitrectomy for various surgical indications

GUEST SPEAKER

Carl D. Regillo, MD, FACS

MODERATORS

Bernard Hurley, MD
Amin Kherani, MD

Schedule

1045 Introduction · Bernard Hurley
1050 Emerging wet AMD treatments · Carl D. Regillo
1120 Discussion
1125 Canadian Preferences & Trends Survey (CAN-PAT) 2015: anti-VEGF treatment of macular edema · Jaspreet Rayat, Parampal Grewal, James Whelan, Matthew Tennant, Netan Choudhry
1130 Discussion
1132 Long-term intraocular pressure changes in patients receiving intravitreal bevacizumab and ranibizumab for treatment of diabetic macular edema · Jason Kwok, Vincent Wu, Davin Johnson, Cody Li, Sanjay Sharma
1137 Q & A
1139 Oral bisphosphonates and risk of age-related macular degeneration · David Maberley, Zaid Mammo, Joanne Matsubara, Michael Guo, Mahyar Etminan
1144 Q & A
1146 A scleral tattoo gone wrong: a case of alcaligenes faecalis endophthalmitis · Paul Freund, Mark Greve
1151 Q & A
1153 27 G vitrectomy: pros and cons · Carl D. Regillo
1208 Discussion
1215 Adjourn

Clinical update: retina

Sunday, June 19, 1545-1715canmeds_diagram_e
Canada Hall 1, Shaw Centre

LEARNING OBJECTIVES

At the end of this session, participants will be able to:

  • Describe how anti-VEGF agents are currently used to treat Diabetic Macular edema
  • Identify choroidal melanoma masqueraders
  • Describe and differentiate different types of epiretinal membranes

GUEST SPEAKERS

Jay S. Duker, MD
Carl D. Regillo, MD, FACS

MODERATORS

Bernard Hurley, MD
James Whelan, MD

FACULTY

Peter Kertes, MD
David Wong, MD
Deepa Yoganathan, MD

Schedule

1545 Use of anti-VEGF agents for diabetic macular edema 2016 · Carl D. Regillo
1600 Melanoma or something else · Jay S. Duker
1615 Characterization of epiretinal membranes and current treatment preferences · David Wong
1630 Retinal innovation 2016 · Deepa Yoganathan
1645 Stem cell therapy for dry AMD · Peter Kertes
1700 Panel discussion
1715 Adjourn

Workshop: Retinal OCT

Monday, June 20, 1045-1215canmeds_diagram_e
Room 202, Shaw Centre

LEARNING OBJECTIVES

At the end of this session, participants will be able to:

  • Describe the basic principle of the working of the OCT, including the latest advance in OCT such as Swept Source OCT, OCT angiography…etc.
  • Interpret the OCT appearance of common macular diseases, such as AMD, diabetic macular, myopia, retinal vein occlusion and vitreoretinal interface diseases including epimacular membrane, macular hole vs. pseudomacular hole, and the latest international classification of vitreomacular traction syndrome
  • Recognize the common and important artifacts of OCT to avoid misinterpretation

GUEST SPEAKERS

Amin Kherani, MD
Simon Lam, MD
Wai-Ching Lam, MD
Pear Pongsachareonnont, MD
Arif Samad, MD

MODERATOR

Wai-Ching Lam, MD

Schedule

1045 Introduction and pre-test questionnaires · Wai-Ching Lam
1050 Basic principle of OCT, including the latest technology · Amin Kherani
1105 Vitreoretinal interface diseases: epimacular membrane, macular hole, lamellar macular hole, pseudomacular hole, vitreomacular traction · Arif Samad
1125 Miscellaneous macular conditions: myopia, AMD, DME, RVO · Simon Lam
1145 Latest advances in OCT, OCT angiography · Pear Pongsachareonnont
1205 Wrap up with post-test questionnaires · Wai-Ching Lam
1215 Adjourn

Retina II

Monday, June 20, 1330-1500canmeds_diagram_e
Room 202, Shaw Centre

LEARNING OBJECTIVES

At the end of this session, participants will be able to:

  • Apply and integrate new SD-OCT angiography techniques into your medical retina practice
  • Describe the clinical findings in choroidermia and demonstrate an understanding of the new treatments for this inherited disease
  • Describe the risk of vitreous hemorrhage associated with new anticoagulants

GUEST SPEAKER

Jay S. Duker, MD

MODERATORS

Netan Choudhry, MD
Arif Samad, MD

Schedule

1330 Introduction and award presentation · Netan Choudhry
1335 What’s new in SD OCT – OCTA and more · Jay S. Duker
1405 3rd prize, COS Award for Excellence in Ophthalmic Research
Choroideremia is a systemic disease with lymphocyte crystals and plasma lipid and RBC membrane abnormalities · Alice Zhang, Naveen Mysore, Hojatollah Vali, Jamie Koenekoop, Sang Ni Cao, Shen Li, Huanan Ren, Vafa Keser, Irma Lopez, Sorath Siddiqui, Ayesha Khan, Kelly Sears, Jim Dixon, Jeremy Schwartzentruber, Jacek Majewski, Nancy Braverman, Robert Koenekoop
1410 Q & A
1412 1st prize, COS Award for Excellence in Ophthalmic Research
The role of VEGF-A in exogenous endophthalmitis: a potential target for immunomodulation · Mark Seamone, Arif Samad, Darrell Lewis, Ian Haidl, Daniel O’Brien, Rishi Gupta, John Dickinson, Jean Marshall, Alan Cruess
1417 Q & A
1419 Ocular gene therapy for choroideremia: the Alberta experience · Ian MacDonald, Stephanie Chan, Rizwan Somani, Matthew Tennant, Ioannis Dimopoulos
1424 Q & A
1426 Microperimetry and early diabetic retinopathy · Samuel N. Markowitz, Mark Mandelcorn, Nupura Bakshi, Michelle Markowitz
1431 Q & A
1433 Risk of intraocular hemorrhage with new oral anticoagulants · George Talany, Michael Guo, Mahyar Etminan
1438 Q & A
1440 A novel spectral domain optical coherence tomography (SD-OCT) classification scheme for the differential diagnosis of macular edema of diabetic and retinal veno-occlusive origin · Mikel Mikhail, Razek Coussa, David Lederer
1445 Q & A
1447 Discussion
1500 Adjourn

Retina III

Monday, June 20, 1545-1715canmeds_diagram_e
Room 202, Shaw Centre

LEARNING OBJECTIVES

At the end of this session, participants will be able to:

  • Describe the current choices available for the treatment of Wet AMD
  • Integrate prone positioning into your practice for the treatment of retinal detachments
  • Describe the economic implications of treatments for retinal detachments
  • Compare and then assess techniques to reduce anxiety and improve sterile delivery of Intravitreal injections

GUEST SPEAKER

Jay S. Duker, MD

MODERATORS

James Whelan, MD
Deepa Yoganathan, MD

Schedule

1545 Current wet AMD therapies – How to choose? · Jay S. Duker
1600 Discussion
1605 Cost comparison of scleral buckle versus vitrectomy in the treatment of rhegmatogenous retinal detachment in Quebec, Canada · Elizabeth Fortin, Benoit Grenier
1610 Q & A
1612 Evaluation of the RETeval 30 Hz flicker ERG in the assessment of diabetic retinopathy · Stuart Coupland, Vanja Popovic, Lynca Kantungane, John Hamilton, Alison Sifton, Merem Faris
1617 Q & A
1619 Primary rhegmatogenous retinal detachment with inferior retinal breaks: 1-day postoperative prone positioning results · Radwan Ajlan, Jordan Isenberg, Ghassan Cordahi, Renaud Duval, Sébastien Olivier, Flavio Rezende
1624 Q & A
1626 Outcomes of intravitreal injections performed with a lid splinting eyelid retraction technique: A minimized sterile approach · Monique Munro, Jessica Ruzicki, Anna Ells, Michael Fielden, Amin Kherani, Patrick Mitchell, Geoff Williams, Feisal Adatia
1631 Q & A
1633 A visual approach to reducing anxiety and improving knowledge transfer for intravitreal injections · Wai-Ching Lam, Crystal Cheung
1638 Q & A
1640 A pilot study of the effect of intravitreal dexamethasone implant (700 micrograms) on diabetic macular edema after cataract surgery · Michael Brent, Pilar Calvo, Fadwa Al Adel, Wantanee Dangboon, Antonio Ferreras
1645 Q & A
1647 Results of half dose photodynamic therapy for chronic central serous retinopathy · Nadeem Dhirani, Sohel Somani
1652 Q & A
1654 Investigating the structural and functional changes to the retina following PRP in diabetic retinopathy patients · Richie Filek
1659 Q & A
1701 Discussion
1715 Adjourn